Phase II study of single agent gemcitabine in patients with hormone refractory prostate cancer (HRPC).

被引：0
|
作者：
Nilsson, S [1 ]
Holmberg, M [1 ]
Ljung, G [1 ]
Pettersson-Skjold, D [1 ]
Blom, R [1 ]
Ullén, A [1 ]
Westberg, R [1 ]
Nilsson, I [1 ]
Lennernas, B [1 ]
机构：
[1] Swedish Prostate Canc Study Grp, Stockholm, Sweden
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4705
引用
收藏
页码：432S / 432S
页数：1
相关论文
共 50 条
  • [1] Phase II study of FK228 in patients with metastatic hormone refractory prostate cancer (HRPC)
    Molife, Rhoda
    Dearnaley, David
    Parker, Chris
    Patterson, Stephen
    Riggs, Charles
    Higano, Celestia
    Stadler, William M.
    McCulloch, William
    Shalaurov, Alex
    de Bono, Johann
    ANNALS OF ONCOLOGY, 2006, 17 : 149 - 149
  • [2] Gemcitabine in hormone-refractory prostate cancer: A phase II study
    Reissigl, A
    Brenner, H
    Chaitchik, S
    Sola, C
    Stackl, W
    Janko, C
    Krejcy, K
    ANNALS OF ONCOLOGY, 1998, 9 : 64 - 64
  • [3] Phase II study of CC-4047 in patients (pts) with metastatic hormone-refractory prostate cancer (HRPC)
    Floissac, M
    Knight, R
    Levin, A
    Glode, LM
    Crawford, ED
    Amato, RJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 410S - 410S
  • [4] A phase II study of sorafenib in combination with bicalutamide in patients with chemo-naive hormone refractory prostate cancer (HRPC)
    Beardsley, E. K.
    Ellard, S. L.
    Holte, S. J.
    North, S. A.
    Winquist, E.
    Chi, K. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] A phase II study of weekly docetaxel (T), estramustine (E), and celecoxib (C) in patients with hormone refractory prostate cancer (HRPC).
    Mellado, B
    Font, A
    Carles, J
    Catalán, G
    Larriba, JLG
    Gallardo, E
    Fernández, LA
    Nogué, M
    Lianes, P
    Del Alba, AG
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 434S - 434S
  • [6] Phase I/II trial of GM-CSF and lenalidomide in patients with hormone refractory prostate cancer (HRPC)
    Dreicer, R.
    Garcia, J.
    Smith, S.
    Elson, P.
    Triozzi, P.
    Hodnick, S.
    Rini, B.
    Klein, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [7] Pilot study of rapamycin in hormone refractory prostate cancer (HRPC) patients (Pts).
    Amato, R
    Sharef, S
    Khan, M
    Zhai, QH
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9136S - 9136S
  • [8] A phase II study of picoplatin with docetaxel and prednisone in chemotherapy-naive patients with metastatic hormone refractory prostate cancer (HRPC)
    Breitz, H. B.
    Roman, L. A.
    Karlov, P. A.
    Cheporov, S. V.
    Lopatkin, N. D.
    Baker, G. S.
    Karlin, D. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] A phase II study of patupilone in patients with metastatic hormone refractory prostate cancer (HRPC) who have progressed after docetaxel
    Chi, K. N.
    Beardsley, E. K.
    Venner, P. M.
    Eigl, B. J.
    Hotte, S. J.
    Ko, Y.
    Saad, F.
    Winquist, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [10] Phase I/II study of weekly docetaxel and vinblastine in the treatment of hormone-refractory prostate cancer (HRPC).
    Ackler, JR
    Tester, WJ
    Leighton, JC
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 771S - 771S
12345